Antengene's ATG-201 Autoimmune Therapy Receives Australian Clinical Trial Approval
Antengene Corporation Limited has received approval from Australia's Human Research Ethics Committee (HREC) to proceed with Phase I clinical trials of ATG-201, the company's proprietary CD19/CD3 bispecific T-cell engager antibody designed to treat B cell-related autoimmune diseases. The Hong Kong-listed biotech firm has also completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration.
The Australian approval follows China's National Medical Products Administration clearance granted in June 2026, demonstrating Antengene's multi-regional development strategy for the experimental therapy. China's pharmaceutical sector has emerged as a significant player in global drug development, with the NMPA approving over 1,300 clinical trial applications for innovative drugs in 2024 alone.
Understanding ATG-201's Mechanism
ATG-201 works by simultaneously binding to CD3 receptors on T cells and CD19 markers on B cells, redirecting the immune system to eliminate disease-causing B cells. This bispecific T-cell engager approach builds on established science: the FDA approved blinatumomab, the first CD19xCD3 bispecific antibody, for hematological malignancies in 2014.
The therapy incorporates steric hindrance masking technology intended to minimize cytokine release syndrome, a serious safety concern with T-cell engaging therapies that can cause fever, hypotension, and organ dysfunction in severe cases. The compound features proprietary CD3 sequences with fast binding kinetics designed to enhance both safety and effectiveness.
B cells play a central role in autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis through autoantibody production, antigen presentation, and cytokine secretion. Recent clinical studies have validated CD19-targeted approaches in autoimmune conditions, with CAR-T cell therapies achieving drug-free remission in lupus patients in trials published in 2024-2025.
Study Design and Objectives
The ATTRACT study will evaluate ATG-201 monotherapy in adult patients with B cell-related autoimmune diseases through two phases: dose escalation and dose expansion. Primary objectives include assessing safety and tolerability while determining the recommended Phase II dose. Secondary endpoints will examine pharmacokinetic and pharmacodynamic profiles, immunogenicity, and preliminary efficacy.
Australia's Clinical Trial Notification scheme allows certain trials to commence 30 business days after notification, provided no objections are raised by regulators or ethics committees, facilitating efficient study initiation.
Partnership and Commercial Context
Antengene has granted Belgium-based UCB exclusive worldwide rights to develop, manufacture, and commercialize ATG-201. UCB, a global biopharmaceutical company with approximately 8,600 employees operating in over 40 countries, focuses on immunology and neurology therapeutic areas. Antengene will conduct the Phase I trials in China and Australia before potentially transferring development responsibilities.
The collaboration positions ATG-201 within the global autoimmune disease therapeutics market, valued at approximately USD 138 billion in 2025 and projected for significant growth driven by increasing disease prevalence and novel biologic therapies.
Company Background
Antengene, which went public on the Hong Kong Stock Exchange in October 2020 raising HK$1.26 billion (USD 162 million), describes itself as a commercial-stage biotech company developing first-in-class and best-in-class medicines. The company's lead commercial asset, XPOVIO (selinexor), a first-in-class oral Selective Inhibitor of Nuclear Export compound originally developed by Karyopharm Therapeutics and licensed to Antengene in 2017, has received approval in ten Asia Pacific markets.
Beyond ATG-201, Antengene's pipeline spans preclinical to commercial stages, with multiple investigational candidates developed through its proprietary AnTenGager platform. The platform incorporates bivalent binding for low-expressing targets and steric hindrance masking across programs targeting various diseases.
The Australian clinical trial approval represents Antengene's strategic expansion from oncology and hematology into autoimmune diseases, targeting areas of significant unmet medical need with differentiated therapeutic approaches.
